Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246173 | 0.97 | ITK (0.54) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245548 | 0.94 | ITK (0.49) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245565 | 0.92 | ITK (0.49) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16246167 | 0.90 | ITK (0.46) | ITKEGFRJAK2BRD4 | |
| SCHEMBL16245581 | 0.87 | ITK (0.52) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245595 | 0.85 | ITK (0.51) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245580 | 0.83 | RPS6KA3 (0.46) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245582 | 0.82 | GSK3B (0.47) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245553 | 0.80 | RPS6KA3 (0.45) | ITKEGFRCA12CA1CA2 | |
| SCHEMBL16245562 | 0.80 | GSK3B (0.47) | ITKEGFRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| EP-2994471-A1 | MACROCYCLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014180524-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014180524-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | ITK 1468/4885EGFR 1412/4885CA12 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.